BioCity Scotland Bo'ness Road Newhouse , Lanarkshire, ML1 5UH United KingdomRoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalized approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. With a net promotor score (NPS) of 82, customers who work with RoukenBio say they would recommend us to colleagues and contacts, and they do! RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across auto-immunity, immuno-oncology, allergy, oncology and inflammation, their team focuses on novel and emerging therapeutic classes including antibodies, biosimilars, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique proprietary enabling technologies, including their customizable inducible cell line platform and their rapid targeted integration cell engineering platform, LocIn, to stay ahead of the curve. In house generation of unique cell-based tools for assays (such as reporter gene cell lines) and subsequent assay design/qualification is a smooth and rapid process. RoukenBio’s assay solutions, including ex vivo patient- derived organoids/3D models, recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.  We also offer cell products that drive breakthrough therapies via our sister organization RoukenCells on Scientist.com Via RoukenCells we provide assay-ready, functionally validated engineered cell lines and primary immune cell banks for therapeutic discovery. Its expanding portfolio spans six core categories: Inducible cell lines – Tunable single- and dual-target IndEx-2 models spanning >30 key immuno-oncology and autoimmune targets. Reporter cell lines – Jurkat, HEK293 and RBL-2H3 luciferase models for measuring T-cell activation and checkpoint blockade, Fc-mediated effector function, cytokine signaling and IgE mediated signaling. Knockout cell lines – License free target knockout models for specificity, target-dependency and mechanism-of-action studies. Immune cell banks – Thaw-and-go cells for functional assays, including antigen-specific CD8+ T cells and expanded nTregs. Overexpressing cell lines – Stable, overexpressing models for binding, screening and potency assays. Targeted integration LocIn kits – CHO-K1 and HEK293 platform cells for rapid, scalable in-house generation of stable, isogenic panels. Enabling Technologies Behind the inducible cell line catalogue lies Rouken's proprietary inducible expression technology (IndEx-2), enabling precise, dose-dependent control of one or two target antigens within the same cellular background. Models covering common immuno-oncology and autoimmune targets, allow researchers to evaluate antigen-density thresholds, therapeutic efficacy, antigen escape and on-target/off-tumor risk. LocIn is Rouken’s proprietary targeted-integration platform, using recombinase-mediated cassette exchange at a defined genomic landing pad to generate stable, isogenic target-expressing cell populations. Ready-made LocIn ReTarget cell lines are engineered at the same predefined locus, reducing position-dependent effects and clone-to-clone variability that can introduce experimental artefacts. This enables cleaner, like-for-like comparison of targets, constructs, orthologues and variants, with observed differences attributed more confidently to the introduced sequence. LocIn Retargeting Kits bring the same technology into customers’ laboratories, enabling stable cell models to be generated in weeks without lengthy subcloning. This provides a faster, more resource-efficient and scalable in-house route to target and pathway validation, therapeutic screening, assay development and mechanism-of-action studies.

Bo'Ness Road Bo'ness Road Newhouse, Scotland, ML1 5UH United KingdomRoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalized approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. With a net promotor score (NPS) of 82, customers who work with RoukenBio say they would recommend us to colleagues and contacts, and they do! RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across auto-immunity, immuno-oncology, allergy, oncology and inflammation, their team focuses on novel and emerging therapeutic classes including antibodies, biosimilars, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique proprietary enabling technologies, including their customizable inducible cell line platform and their rapid targeted integration cell engineering platform, LocIn, to stay ahead of the curve. In house generation of unique cell-based tools for assays (such as reporter gene cell lines) and subsequent assay design/qualification is a smooth and rapid process. RoukenBio’s assay solutions, including ex vivo patient- derived organoids/3D models, recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.  We also offer cell products that drive breakthrough therapies via our sister organization RoukenCells on Scientist.com Via RoukenCells we provide assay-ready, functionally validated engineered cell lines and primary immune cell banks for therapeutic discovery. Its expanding portfolio spans six core categories: Inducible cell lines – Tunable single- and dual-target IndEx-2 models spanning >30 key immuno-oncology and autoimmune targets. Reporter cell lines – Jurkat, HEK293 and RBL-2H3 luciferase models for measuring T-cell activation and checkpoint blockade, Fc-mediated effector function, cytokine signaling and IgE mediated signaling. Knockout cell lines – License free target knockout models for specificity, target-dependency and mechanism-of-action studies. Immune cell banks – Thaw-and-go cells for functional assays, including antigen-specific CD8+ T cells and expanded nTregs. Overexpressing cell lines – Stable, overexpressing models for binding, screening and potency assays. Targeted integration LocIn kits – CHO-K1 and HEK293 platform cells for rapid, scalable in-house generation of stable, isogenic panels. Enabling Technologies Behind the inducible cell line catalogue lies Rouken's proprietary inducible expression technology (IndEx-2), enabling precise, dose-dependent control of one or two target antigens within the same cellular background. Models covering common immuno-oncology and autoimmune targets, allow researchers to evaluate antigen-density thresholds, therapeutic efficacy, antigen escape and on-target/off-tumor risk. LocIn is Rouken’s proprietary targeted-integration platform, using recombinase-mediated cassette exchange at a defined genomic landing pad to generate stable, isogenic target-expressing cell populations. Ready-made LocIn ReTarget cell lines are engineered at the same predefined locus, reducing position-dependent effects and clone-to-clone variability that can introduce experimental artefacts. This enables cleaner, like-for-like comparison of targets, constructs, orthologues and variants, with observed differences attributed more confidently to the introduced sequence. LocIn Retargeting Kits bring the same technology into customers’ laboratories, enabling stable cell models to be generated in weeks without lengthy subcloning. This provides a faster, more resource-efficient and scalable in-house route to target and pathway validation, therapeutic screening, assay development and mechanism-of-action studies.

Antibody Analytics Discovery Centre Braidhurst Industrial Estate, Newhut Road Motherwell, ML1 3ST United KingdomRoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalized approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. With a net promotor score (NPS) of 82, customers who work with RoukenBio say they would recommend us to colleagues and contacts, and they do! RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across auto-immunity, immuno-oncology, allergy, oncology and inflammation, their team focuses on novel and emerging therapeutic classes including antibodies, biosimilars, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique proprietary enabling technologies, including their customizable inducible cell line platform and their rapid targeted integration cell engineering platform, LocIn, to stay ahead of the curve. In house generation of unique cell-based tools for assays (such as reporter gene cell lines) and subsequent assay design/qualification is a smooth and rapid process. RoukenBio’s assay solutions, including ex vivo patient- derived organoids/3D models, recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.  We also offer cell products that drive breakthrough therapies via our sister organization RoukenCells on Scientist.com Via RoukenCells we provide assay-ready, functionally validated engineered cell lines and primary immune cell banks for therapeutic discovery. Its expanding portfolio spans six core categories: Inducible cell lines – Tunable single- and dual-target IndEx-2 models spanning >30 key immuno-oncology and autoimmune targets. Reporter cell lines – Jurkat, HEK293 and RBL-2H3 luciferase models for measuring T-cell activation and checkpoint blockade, Fc-mediated effector function, cytokine signaling and IgE mediated signaling. Knockout cell lines – License free target knockout models for specificity, target-dependency and mechanism-of-action studies. Immune cell banks – Thaw-and-go cells for functional assays, including antigen-specific CD8+ T cells and expanded nTregs. Overexpressing cell lines – Stable, overexpressing models for binding, screening and potency assays. Targeted integration LocIn kits – CHO-K1 and HEK293 platform cells for rapid, scalable in-house generation of stable, isogenic panels. Enabling Technologies Behind the inducible cell line catalogue lies Rouken's proprietary inducible expression technology (IndEx-2), enabling precise, dose-dependent control of one or two target antigens within the same cellular background. Models covering common immuno-oncology and autoimmune targets, allow researchers to evaluate antigen-density thresholds, therapeutic efficacy, antigen escape and on-target/off-tumor risk. LocIn is Rouken’s proprietary targeted-integration platform, using recombinase-mediated cassette exchange at a defined genomic landing pad to generate stable, isogenic target-expressing cell populations. Ready-made LocIn ReTarget cell lines are engineered at the same predefined locus, reducing position-dependent effects and clone-to-clone variability that can introduce experimental artefacts. This enables cleaner, like-for-like comparison of targets, constructs, orthologues and variants, with observed differences attributed more confidently to the introduced sequence. LocIn Retargeting Kits bring the same technology into customers’ laboratories, enabling stable cell models to be generated in weeks without lengthy subcloning. This provides a faster, more resource-efficient and scalable in-house route to target and pathway validation, therapeutic screening, assay development and mechanism-of-action studies.

Rouken Discovery Centre Braidhurst Industrial Estate, Newhut Road Motherwell, ML1 3ST United KingdomRoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalized approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. With a net promotor score (NPS) of 82, customers who work with RoukenBio say they would recommend us to colleagues and contacts, and they do! RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across auto-immunity, immuno-oncology, allergy, oncology and inflammation, their team focuses on novel and emerging therapeutic classes including antibodies, biosimilars, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique proprietary enabling technologies, including their customizable inducible cell line platform and their rapid targeted integration cell engineering platform, LocIn, to stay ahead of the curve. In house generation of unique cell-based tools for assays (such as reporter gene cell lines) and subsequent assay design/qualification is a smooth and rapid process. RoukenBio’s assay solutions, including ex vivo patient- derived organoids/3D models, recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.  We also offer cell products that drive breakthrough therapies via our sister organization RoukenCells on Scientist.com Via RoukenCells we provide assay-ready, functionally validated engineered cell lines and primary immune cell banks for therapeutic discovery. Its expanding portfolio spans six core categories: Inducible cell lines – Tunable single- and dual-target IndEx-2 models spanning >30 key immuno-oncology and autoimmune targets. Reporter cell lines – Jurkat, HEK293 and RBL-2H3 luciferase models for measuring T-cell activation and checkpoint blockade, Fc-mediated effector function, cytokine signaling and IgE mediated signaling. Knockout cell lines – License free target knockout models for specificity, target-dependency and mechanism-of-action studies. Immune cell banks – Thaw-and-go cells for functional assays, including antigen-specific CD8+ T cells and expanded nTregs. Overexpressing cell lines – Stable, overexpressing models for binding, screening and potency assays. Targeted integration LocIn kits – CHO-K1 and HEK293 platform cells for rapid, scalable in-house generation of stable, isogenic panels. Enabling Technologies Behind the inducible cell line catalogue lies Rouken's proprietary inducible expression technology (IndEx-2), enabling precise, dose-dependent control of one or two target antigens within the same cellular background. Models covering common immuno-oncology and autoimmune targets, allow researchers to evaluate antigen-density thresholds, therapeutic efficacy, antigen escape and on-target/off-tumor risk. LocIn is Rouken’s proprietary targeted-integration platform, using recombinase-mediated cassette exchange at a defined genomic landing pad to generate stable, isogenic target-expressing cell populations. Ready-made LocIn ReTarget cell lines are engineered at the same predefined locus, reducing position-dependent effects and clone-to-clone variability that can introduce experimental artefacts. This enables cleaner, like-for-like comparison of targets, constructs, orthologues and variants, with observed differences attributed more confidently to the introduced sequence. LocIn Retargeting Kits bring the same technology into customers’ laboratories, enabling stable cell models to be generated in weeks without lengthy subcloning. This provides a faster, more resource-efficient and scalable in-house route to target and pathway validation, therapeutic screening, assay development and mechanism-of-action studies.

Rouken Discovery Centre Braidhurst Industrial Estate, Newhut Road Motherwell, Lanarkshire, ML1 3ST United KingdomRoukenBio – CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalized approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. With a net promotor score (NPS) of 82, customers who work with RoukenBio say they would recommend us to colleagues and contacts, and they do! RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across auto-immunity, immuno-oncology, allergy, oncology and inflammation, their team focuses on novel and emerging therapeutic classes including antibodies, biosimilars, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique proprietary enabling technologies, including their customizable inducible cell line platform and their rapid targeted integration cell engineering platform, LocIn, to stay ahead of the curve. In house generation of unique cell-based tools for assays (such as reporter gene cell lines) and subsequent assay design/qualification is a smooth and rapid process. RoukenBio’s assay solutions, including ex vivo patient- derived organoids/3D models, recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.  We also offer cell products that drive breakthrough therapies via our sister organization RoukenCells on Scientist.com Via RoukenCells we provide assay-ready, functionally validated engineered cell lines and primary immune cell banks for therapeutic discovery. Its expanding portfolio spans six core categories: Inducible cell lines – Tunable single- and dual-target IndEx-2 models spanning >30 key immuno-oncology and autoimmune targets. Reporter cell lines – Jurkat, HEK293 and RBL-2H3 luciferase models for measuring T-cell activation and checkpoint blockade, Fc-mediated effector function, cytokine signaling and IgE mediated signaling. Knockout cell lines – License free target knockout models for specificity, target-dependency and mechanism-of-action studies. Immune cell banks – Thaw-and-go cells for functional assays, including antigen-specific CD8+ T cells and expanded nTregs. Overexpressing cell lines – Stable, overexpressing models for binding, screening and potency assays. Targeted integration LocIn kits – CHO-K1 and HEK293 platform cells for rapid, scalable in-house generation of stable, isogenic panels. Enabling Technologies Behind the inducible cell line catalogue lies Rouken's proprietary inducible expression technology (IndEx-2), enabling precise, dose-dependent control of one or two target antigens within the same cellular background. Models covering common immuno-oncology and autoimmune targets, allow researchers to evaluate antigen-density thresholds, therapeutic efficacy, antigen escape and on-target/off-tumor risk. LocIn is Rouken’s proprietary targeted-integration platform, using recombinase-mediated cassette exchange at a defined genomic landing pad to generate stable, isogenic target-expressing cell populations. Ready-made LocIn ReTarget cell lines are engineered at the same predefined locus, reducing position-dependent effects and clone-to-clone variability that can introduce experimental artefacts. This enables cleaner, like-for-like comparison of targets, constructs, orthologues and variants, with observed differences attributed more confidently to the introduced sequence. LocIn Retargeting Kits bring the same technology into customers’ laboratories, enabling stable cell models to be generated in weeks without lengthy subcloning. This provides a faster, more resource-efficient and scalable in-house route to target and pathway validation, therapeutic screening, assay development and mechanism-of-action studies.